Stemline Therapeutics, Inc. (NASDAQ:STML) COO Kenneth Hoberman sold 9,110 shares of the business’s stock in a transaction that occurred on Tuesday, January 10th. The stock was sold at an average price of $13.82, for a total value of $125,900.20. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of Stemline Therapeutics, Inc. (NASDAQ:STML) opened at 12.95 on Friday. The company has a 50-day moving average price of $12.30 and a 200 day moving average price of $9.96. Stemline Therapeutics, Inc. has a 1-year low of $3.88 and a 1-year high of $14.60. The company’s market capitalization is $231.11 million.

ILLEGAL ACTIVITY NOTICE: “Stemline Therapeutics, Inc. (STML) COO Sells $125,900.20 in Stock” was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this story on another domain, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at http://www.dailypolitical.com/2017/01/14/stemline-therapeutics-inc-stml-coo-sells-125900-20-in-stock.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC bought a new position in Stemline Therapeutics during the third quarter worth $400,000. Paradigm Asset Management Co. LLC bought a new position in Stemline Therapeutics during the second quarter worth $141,000. State Street Corp raised its position in Stemline Therapeutics by 1.9% in the second quarter. State Street Corp now owns 220,768 shares of the biopharmaceutical company’s stock worth $1,493,000 after buying an additional 4,197 shares in the last quarter. Rhumbline Advisers raised its position in Stemline Therapeutics by 20.9% in the second quarter. Rhumbline Advisers now owns 26,260 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 4,538 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in Stemline Therapeutics by 11.8% in the second quarter. Franklin Resources Inc. now owns 2,102,200 shares of the biopharmaceutical company’s stock worth $14,232,000 after buying an additional 222,170 shares in the last quarter. Institutional investors own 46.73% of the company’s stock.

A number of research analysts recently weighed in on STML shares. Zacks Investment Research raised Stemline Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Wednesday, October 5th. Wedbush reissued an “outperform” rating and set a $15.00 target price on shares of Stemline Therapeutics in a report on Tuesday, December 6th. Roth Capital reissued a “buy” rating and set a $32.00 target price on shares of Stemline Therapeutics in a report on Wednesday, November 23rd. Finally, HC Wainwright reissued a “buy” rating on shares of Stemline Therapeutics in a report on Monday, November 21st. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $23.20.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

5 Day Chart for NASDAQ:STML

Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.